Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (Nasdaq: DRIO) presented new clinical research at the ADA 81^st Scientific Sessions, highlighting the effectiveness of its AI-driven personalization engine. The study involved 9,794 users, showing a 56% increase in engagement and a 12% reduction in average high-blood glucose readings over six months. A second study with 11,101 Type 2 diabetes members revealed a significant rise in target in-range readings from 28.4% to 54.8% over a year. These findings underscore Dario's commitment to enhancing health management through tailored interventions.

DarioHealth Corp. (Nasdaq: DRIO) has been selected as the digital health provider for Coastal Family Health Center, focusing on Remote Patient Monitoring (RPM) for hypertension. This initiative targets the high rate of hypertension in Mississippi, enabling better management for over 4,500 patients. Dario's AI-driven platform enhances patient-provider interactions and aims to reduce cardiac events and hospital admissions. The company plans to announce more B2B clients shortly, reinforcing its market position in digital therapeutics.

DarioHealth Corp. (NASDAQ: DRIO) has launched the Upright GO S, a wearable sensor designed to enhance back health accessibility. This product aligns with Dario's growth strategy, targeting both business partnerships and consumer markets. Currently, Dario boasts over 185,000 platform members. The Upright GO S aims to meet the rising demand for affordable musculoskeletal care, particularly as chronic back pain becomes prevalent among lower socioeconomic groups. The device is expected to diversify user engagement by utilizing AI-driven personalization, enhancing user experience across demographics.

DarioHealth Corp. (Nasdaq: DRIO) announced its inclusion in the Russell 3000® and Russell 2000® Indexes, effective June 28, 2021, following the annual reconstitution. This inclusion reflects Dario's growth as a pioneer in digital therapeutics and is expected to enhance company visibility among institutional investors, as approximately $9 trillion in assets are benchmarked to Russell indexes. CEO Erez Raphael highlighted the achievement as a testament to the team's efforts in revolutionizing chronic disease management through AI-powered solutions.

DarioHealth Corp. (Nasdaq: DRIO) has completed the acquisition of PsyInnovations, Inc. (wayForward) for $30 million, comprising $6 million in cash and up to $24 million in stock, contingent on meeting revenue targets in 2022. Approximately 898,500 shares will be issued at a price of $21.09 per share, with an additional 237,000 shares available based on performance. The founders of PsyInnovations will join DarioHealth, bringing expertise in behavioral health, enhancing Dario's digital therapeutic offerings.

DarioHealth Corp. (NASDAQ: DRIO) announced results from a study presented at the 14th International Conference on Advanced Technologies and Treatments for Diabetes. The research focused on the effects of Dario's personalized digital interventions on diabetes self-management, involving 246 users. Key findings included a 14% and 22% increase in the percentage of users measuring blood glucose within the first 30 days and 30-60 days, respectively, along with improvements in measurement frequency and recency. Experts emphasized the potential life-changing benefits of these personalized solutions for diabetes management.

DarioHealth Corp. (Nasdaq: DRIO) announced its participation in the Stifel 2021 Virtual Cross Sector Insight Conference, scheduled for June 9, 2021, at 8:00 a.m. ET. CEO Erez Raphael and President Rick Anderson will present in a virtual format. Interested attendees can access both live and archived webcasts via DarioHealth's investor website. DarioHealth is a leader in digital therapeutics, offering AI-powered solutions that help individuals manage chronic conditions effectively. The company is expanding its services across various regions and medical conditions.

DarioHealth Corp. (Nasdaq: DRIO) announced a new study on its digital therapeutics for Type 2 diabetes published in the Journal of Diabetes Science and Technology. The study showed a 2.0% reduction in average HbA1c values among participants using the Dario app alongside certified coaching. Other notable findings included an 18% reduction in fasting blood glucose and a 10% reduction in BMI. The research highlights the effectiveness of combining digital self-monitoring with live coaching, supporting Dario's mission to enhance diabetes management.

DarioHealth Corp. (Nasdaq: DRIO) will participate in the 18th Annual Craig-Hallum Institutional Investor Conference on June 2. CEO Erez Raphael and President Rick Anderson will host meetings with registered investors. DarioHealth is a leader in digital therapeutics, focusing on chronic condition management through AI-powered solutions. Their tools promote behavioral change and improve health outcomes, with a strong reputation in diabetes and hypertension care. For more information, visit dariohealth.com.